35results about How to "To achieve the effect of tumor treatment" patented technology

The invention relates to a probe based on mesoporous carbon nanospheres doped with gold nanoparticle materials and a preparation method thereof. The probe comprises mesoporous carbon nanospheres, gold nanoparticles grown on the inner channel walls of the mesoporous carbon nanospheres, Organic fluorescent substances loaded in the channels of mesoporous carbon nanospheres and targeting molecules connected on the surface of mesoporous carbon nanospheres through chemical bonds. Compared with the prior art, the present invention can not only realize diagnostic monitoring, but also can be used as a therapeutic probe, and has good targeting and excellent therapeutic effect based on PTT and PDT. Finally, the synthesized probes successfully ablated tumors (tumors of MGC-803 cells in tumor-bearing mice) and were subjected to in vivo and in vitro fluorescence imaging. In addition, the gold particles located inside the mesoporous carbon nanospheres are not only well protected, but also fully play the role of nanozyme catalysis.

The present invention relates to a kind of near-infrared two-region conjugated nanoparticles and its preparation method and application. The near-infrared two-region conjugated nanoparticles include near-infrared two-region conjugated small molecules and amphiphilic polymers; the near-infrared two-region The structural formula of the conjugated small molecule is as follows: the amphiphilic polymer self-assembles and wraps on the conjugated small molecule in the second near-infrared region. The nanoparticle has good biocompatibility, high photothermal conversion efficiency in the second near-infrared region, good photoacoustic imaging effect and photothermal treatment effect on tumors in the second near-infrared region.

The invention discloses a complex frequency ultrasonic tumor treatment head. The complex frequency ultrasonic tumor treatment head is characterized by comprising an ultrasonic transducer, the ultrasonic transducer comprises a double-end stud, a rear cover board, a front cover board and an insulation sleeve located on the middle section of the double-end stud, and the rear cover board and the front cover board are located on a front thread section and a rear thread section of the double-end stud respectively and compress a first insulation ceramic wafer, a rear piezoelectric ceramic stack, a second insulation ceramic wafer, a mass block, a third insulation ceramic wafer, a front piezoelectric ceramic stack and a fourth insulation ceramic wafer which are sequentially connected to the insulation sleeve in a sleeved mode. A signal generator is utilized for transmitting two signal frequencies, the two piezoelectric ceramic stacks at the two ends of the mass block in the transducer are made to vibrate at different frequencies, the transducer works at a double-frequency mode, the cavitation effect is enhanced through the low frequency generated by difference frequency in the double frequencies, tumor angiogenesis is induced to form thrombus, a tumor nutrition feeding channel is blocked, and the effect of treating a tumor is achieved. The complex frequency ultrasonic tumor treatment head is simple in structure, low in manufacturing cost, and easy and convenient to operate.

The invention relates to the technical field of biomedical technology, and discloses lysosome-targeted pH-sensitive nanoparticle, comprising adriamycin calcium complex Ca-DOX cluster formed by chelating calcium ions Ca<2+> with adriamycin DOX. Fibroin is attached to the surface of the adriamycin calcium complex Ca-DOX cluster. The invention can enable more nanoparticles to be swallowed into the lysine body by cells, the aggregation degree and effective drug loading of nanoparticles in tumor region are improved, and accelerated the decomposition of nanoparticles in lysosomes, so that more Ca<2+> and CO2 are released, adriamycin can be released from the lysosome and enter the cell nucleus to play an anti-tumor role, thus effectively improving the lethality of the tumor, achieving the effectof tumor treatment, and providing a new direction for the clinical treatment of tumor.

The invention provides an anti-tumor ANXA1 derived polypeptide and its application. A series of experimental results confirmed that ANXA1 protects EphA2 from being ubiquitinated and degraded by E3 ubiquitin ligase Cbl by binding to EphA2. ) is the key region for the combination of ANXA1 and EphA2. In order to block the combination of ANXA1 and EphA2, ANXA1 N-terminal 20‑30 amino acid polypeptides were synthesized in vitro, and entered into tumor cells with the help of the membrane-penetrating peptide TAT, which could significantly block the combination of ANXA1 and EphA2 in tumor cells, increase the combination of Cbl and EphA2, and promote The ubiquitination and degradation of EphA2 inhibits the growth of tumor cells in vitro and in vivo, and has a significant antitumor effect. Therefore, the EYVQTVKSSKG polypeptide can be used to prepare antitumor drugs and has important clinical application value.

The present invention belongs to the preparation process of transgenic tumor cell for treating malignant tumor, and is especially the preparation process of tumor cell containing interleukin-23 transgene. The tumor treating method of the present invention is superior to available tumor treating methods. Interleukin-23 gene is introduced via carrier into tumor cell to produce interleukin-23 with powerful tumor resisting effect to treat malignant tumor. It functions in the initial immune response stage and activate dendritic cell to induce natural killing of cell. Interleukin-23 can also induce the proliferation and activation of memory T cell, secret IFN-gamma, regulate immunological function, inhibit the vascularization in tumor part and thus reach the effect of curing malignant tumor.

The invention provides the use of the long-chain non-coding RNA RP11‑224O19.2 inhibitor in the preparation of drugs for treating tumors. The invention also provides a drug for treating tumors and a liver cancer screening and / or liver cancer prognosis diagnosis kit. The present invention shows that the RP11‑22O19.2 inhibitor has a significant therapeutic effect on tumors. In addition, detecting the expression level of RP11-224O19.2 can be used for auxiliary diagnosis and prognosis judgment of clinical liver cancer, and has a good application prospect.